A unique platform offers a first-of-its-kind technology for allowing implantation of a biological bioprosthesis to replace a leaky mitral valve through catheterization only.

The novel RoseDoc platform developed by TruLeaf Medical (Or Akiva,Israel; www.truleaf-medical.com) enables a ground-breaking procedure that is minimally invasive,performed on a beating heart via two needle punctures without surgery or the use of a heart-lung machine.

The procedure is asociated with significantly lower risk than traditional open-heart mitral valve surgery.

This means that millions of patients across the world, who until now were considered to be inoperable,can receive a new valve and look forward to a substantial improvement in their functional capacity,quality of life and life expectancy.